Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label ...

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and ...

Patients with osteoporosis who suffer a fragility fracture at age 80 years or older have better five-year outcomes if they receive treatment for osteoporosis, according to a study presented at ENDO ...

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx ...

SAN FRANCISCO -- Crinecerfont (Crenessity) may help improve metabolic profiles of adults and children with classic congenital ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

ENDO 2025 spotlights breakthrough research in PCOS, obesity, diabetes, and rare endocrine disorders and offers practical updates for daily clinical care. As the sun rises over San Francisco, ...

Closing of the Merger Expected in Early August DUBLIN, July 17, 2025 /PRNewswire/ -- Mallinckrodt plc today announced that the Irish High Court has given the necessary ruling to enable ...

Sweetener consumption and genetic predisposition are independently associated with the risk for central precocious puberty (CPP), according to a study presented at ENDO 2025, the annual meeting of the ...

Research from ENDO 2025 reveals that GLP-1 anti-obesity medications not only aid in weight loss but also improve testosterone ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...

Adrenal adenomas were associated with attenuated weight loss among patients with obesity or overweight using GLP-1 or GIP/GLP-1 RAs.